| Literature DB >> 21343889 |
Christian Blenn1, Philippe Wyrsch, Felix R Althaus.
Abstract
DNA damage to cells activates nuclear poly(ADP-ribose)polymerases (PARPs) and the poly(ADP-ribose) (PAR) synthesized is rapidly cleaved into ADP-ribose (ADPR) by PAR glycohydrolase (PARG) action. Naturally appearing tannin-like molecules have been implicated in specific inhibition of the PARG enzyme. This review deals with the in vitro and in vivo effects of tannins on PAR metabolism and their downstream actions in DNA damage signaling.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21343889 PMCID: PMC6259645 DOI: 10.3390/molecules16021854
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Poly(ADP-ribose) metabolism. In response to DNA damage, nuclear poly(ADP-ribose)polymerases (PARP-1 and PARP-2) hydrolyze NAD+, releasing ADPR, nicotinamide and H+. This reaction is induced by the formation of an ester bond between the amino acid-acceptors glutamic acid, aspartic acid or COOH-lysine and the first ADP-ribose (ADPR, marked in blue). Elongation occurs at the 2′-OH of the ribose moiety whereas branching occurs at the 2″-OH position resulting in poly(ADPR) (PAR), a multi-branched polyanion. Poly(ADPR)glycohydrolase (PARG) is a catabolic enzyme with an endo- and exoglycosidic activity. It cleaves the glycosidic bonds between the ADPR units, resulting in free PAR and finally ADPR.
Figure 2Chemical structures of galloyl derivates tested as PARG inhibitors with efficiency in cells and/or in vitro.
Inhibitory potential of tannins, related molecules as well as other known PARG inhibitors in enzymatic in vitro assays.
| Compound | IC50 (µM) | Reference | |||
|---|---|---|---|---|---|
| Gallotannins | |||||
| Trigalloylglucose | 33.4 ± 3.1 | [ | |||
| 31.8 ± 2.8 | [ | ||||
| 3-galloyl-α,β-D-glucose | 0.95 ± 0.02 | [ | |||
| 3-galloyl-O-methyl-α,β-D-glucose | 7.1 ± 0.05 | [ | |||
| 2-galloyl-O-methyl-α,β-D-glucose | 7.2 ± 0.03 | [ | |||
| Tetragalloylglucose | 24.8 ± 2.0 | [ | |||
| 24.2 ± 1.9 | [ | ||||
| Pentagalloylglucose | 17.8 ± 1.2 | [ | |||
| 18.9 ± 1.1 | [ | ||||
| Gallotannin mix | 16.8 ± 28.9 | [ | |||
| Ellagitannins | |||||
| Monomer | |||||
| Tellimagrandin I | 10.8 ± 0.6 | [ | |||
| 11.9 ± 0.5 | [ | ||||
| Casuarictin | 13.3 ± 0.7 | [ | |||
| 11.7 ± 0.6 | [ | ||||
| Geraniin | 18.4 ± 0.7 | [ | |||
| 15.5 ± 0.6 | [ | ||||
| Dimer | |||||
| Cornusiin A | 5.1 ± 0.2 | [ | |||
| 7.1 ± 0.3 | [ | ||||
| Rugosin D | 5.8 ± 0.3 | [ | |||
| 6.1 ± 0.4 | [ | ||||
| Coriariin A | 8.1 ± 0.5 | [ | |||
| 8.5 ± 0.5 | [ | ||||
| Nobotanin B | 4.8 ± 0.4 | [ | |||
| 4.4 ± 0.3 | [ | ||||
| 15 | [ | ||||
| Oenothein B | 4.8 ± 0.4 | [ | |||
| 3.8 | [ | ||||
| Trimer | |||||
| Nobotanin E | 1.4 ± 0.2 | [ | |||
| 1.8 ± 0.2 | [ | ||||
| Tetramer | |||||
| Nobotanin K | 0.44 ± 0.03 | [ | |||
| 0.38 ± 0.03 | [ | ||||
| Ellagitannin mix | 8.3 ± 12.5 | [ | |||
| (-)-Epicatechin gallate | |||||
| Monomer | >100 | [ | |||
| >100 | [ | ||||
| Dimer | >100 | [ | |||
| >100 | [ | ||||
| Trimer | >100 | [ | |||
| >100 | [ | ||||
| Tetramer | >100 | [ | |||
| >100 | [ | ||||
| Gallic acid | >100 | [ | |||
| Ellagic acid | >100 | [ | |||
| (-)-Epicatechin | >100 | [ | |||
| (-)-Epigallocatechin | >100 | [ | |||
| Benzoic acid | >100 | [ | |||
| Glucose | >100 | [ | |||
| ADP-HPD | 0.33 | [ | |||
| 0.136 | [ | ||||
| 0.66 | [ | ||||
| 0.12 | [ | ||||
| 1.7 | [ | ||||
| Eosin Y | 1.9 | [ | |||
| GPI18214 | 3 | [ | |||
| Phloxine B | 5 | [ | |||
| Ethacridine | 7.2 | [ | |||
| Adenosine cyclic 3’, 5’-monophosphate | 300 | [ | |||
| ADP-ribose | 3200 | [ | |||
| 1100 | [ | ||||
Tannin derivatives as PARG inhibitor in cell culture models.
| Author | Cell system | Stressor | Compound | Effects |
|---|---|---|---|---|
| Tsai 1992 [ | 34I cells (C3H mouse mammarian carcinoma) | Dexamethasone | Nobotanin B | PAR-degradation of HMG 14, 17 and histone H1 blocked, but not on HMG1 and HMG2; Glucocorticoid-regulated MMTV (=Mouse mammary tumor virus) mRNA synthesis ↓; Bioavailability: 0.3%. |
| Aoki 1995 [ | 34I cells (C3H mouse mammarian carcinoma) | Dexamethasone | Nobotanin B/Oenothein B | Glucocorticoid-regulated MMTV mRNA synthesis ↓; Oenothein B → depoly(ADP-ribosylation of HMG 14 and 17 ↓ but not HMG 1, 2 and histone H1. |
| Ying 2000 [ | Murine astro-cytes from ICR mice | H2O2 | Gallotannin | Preincubated dose-dependent cell death ↓ (24 and 72 h); No effect under parallel treatment with H2O2. |
| Ying 2001 [ | Neurons from Swiss-Webster mice | H2O2 | Nobotanin B/Gallotannin | Nobotanin B and gallotannin → H2O2- |
| Astrocytes from Swiss- Webster mice | Cell death ↓; Prevents NAD+ drop (10 min); PAR-degradation (5, 10min) ↓; Negligible anti-oxidative effect. | |||
| Bakondi 2004 [ | HaCaT (Human kera- tinocytes) | H2O2, ONOO- | Gallotannin | Cytotoxic; Caspase 3-activity (6 h) ↓; No effect on PAR accumulation; PAR-PARP-1 automodification ↓; NAD+ drop after 0.5, 1 and 2 h ↓. |
| Di Meglio 2004 [ | Rat germinal cells | SIN-1, SNO | Gallotannin | DNA repair ↓. |
| Dumitriu 2004 [ | PBMC (Human peripheral blood mono-nuclear cells) | UVB | Gallotannin | Inhibition of ABC transporters following irradiation ↓. |
| Falsig 2004 [ | Primary astro- cytes (C57bl/6jbom mice) | H2O2, SIN-1 | Gallotannin | Cell death ↓; No effect on PAR. |
| Keil 2004 [ | HeLa (nuclear extracts) | Gallotannin | PAR levels | |
| Rapizzi 2004 [ | RAW 264.7 (Murine macro- phages) | MNNG, LPS, IFN-γ, H2O2 | Gallotannin | |
| Uchiumi 2004 [ | HL-60 (Human pro- myelocytic leu- kemia cells) | 12-O-tetradeca- noylphorbol-13- acetate | Gallotannin | Nuclear PARG activity (3 h) ↓ but not cyto- plasmic; Basal relative PARG expression ↓. |
| Erdelyi 2005 [ | A549 (Human lung adenocar- cinoma epithelial cells) | TNFα, IL-1β | Gallotannin | 4 h after treatment: MCP-1 ↓; MIP-1β ↓; |
| Maruta 2007 [ | Mid-S phase cell nuclei of HeLa cells | Oenothein B | DNA replication activity ↓. | |
| Formentini 2008 [ | HeLa (Human cervical cancer cells) | MNNG | 3-galloyl-α,β- | PAR degradation 15 and 30 min ↓; Cell death after 3 or 6 h ↓; AIF release ↓ (1 h, MNNG); No DNA strand break induction |
| Tikoo 2010 [ | H9c2 embryonic rat heart myoblasts | Doxorubicin | Gallotannin | Cell death ↓; Cytoplasmic vacuolization ↓; Bax ↓; Bcl-2 ↑; PARP-1 cleavage ↓. |
| MDA-MB-231 breast cancer cells | Toxicity of doxorubicin ↑; Gallotannin is toxic |
Effects of the potential PARG inhibitor gallotannin in animals.
| Author | Animals | Model | Compound | Key findings |
|---|---|---|---|---|
| Tikoo 2007 [ | Male Sprague-Dawley Rats | Model of nephrotoxicity (Cisplatin) | Gallotannin (intraperito-neal) | Co-treatment of gallotannin → nephrotoxicity ↑: (BUN ↑; Plasma creatinine ↑; Plasma albumin ↑); PARP-1 cleavage ↓; Tubular damage ↓. Post-treatment → toxicity ↓: (BUN ↓; Plasma creatinine ↓; Plasma albumin ↓); Tubular damage ↓; PARP-1 cleavage ↓. |
| Tikoo 2008 [ | Male Swiss albino mice | Antiretroviral drug (Azidothymidine) | Gallotannin (intraperito-neal) | Gallotannin is hepatoprotective after azidothymidine. Oxidative stress ↓ (TBARS ↓, GSH ↓); ALT ↓; AST ↓; Alkaline phosphatase ↓; Micronuclei for- mation ↓; Vacuolization ↓; Fine inflammatory in- filtrations ↓; Fatty degeneration of hepatocytes ↓; Histone acetylation ↓; PARP-1 cleavage (89 kDa) ↓. |
| Wei 2007 [ | Male Sprague-Dawley Rats | Model for ischemia/reperfusion injury (Intraluminal middle cerebral artery oc- clusion) | Gallotannin (intranasal) | Gallotannin protects against ischemia/reperfusion size ↓; Neurological deficits ↓; Nuclear PAR ↑ (4 and 16 h); AIF translocation ↓ (4 and 16 h). 5 h gallotannin after reperfusion: Infarct size ↓; Neurological deficits ↓. |
| Chandak 2009 [ | Male Sprague- Dawley Rats | Model of diabetes I (Streptozotocin) | Gallotannin (intraperito-neal) | No effect on body weight, plasma glucose, BUN and urine proteine. Glomerular hypertrophy ↓; Plasma creatinine ↓; PARP-1 cleavage (24 kDa) ↓. |
| Tikoo 2010 [ | Female Sprague- Dawley Rats | Breast cancer model (7,12-dimethyl benz(a)anthracene/ doxorubicin) | Gallotannin (intraperito- neal) | Gallotannin shows protection against doxorubicin- induced cardiotoxicity. Heart weight ↑; Relative heart weight ↑; TBARS ↑; Bax expression ↓; Plasma LDH ↓; Cytoplasmic vacuolization ↓; Myofibrils ↑; PARP-1 116 kDa + 89 kDa ↓; p53 ↑; But potentiates doxorubicin toxicity in breast tumors. |